GHDX Related Analyst Ratings
-
Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
-
Oppenheimer Initiates Coverage on Genomic Health (GHDX) with a Perform
-
J.P. Morgan Downgrades Genomic Health (GHDX) to Neutral
-
RBC Capital Upgrades Genomic Health (GHDX) to Outperform
-
Cantor Fitzgerald Upgrades Genomic Health (GHDX) to Buy
-
Leerink Swann Downgrades Genomic Health (GHDX) to Market Perform
-
RBC Upgrades Genomic Health (GHDX) to Sector Perform
-
Leerink Swann Starts Genomic Health (GHDX) with an Outperform Rating
-
Piper Jaffray upgrades Genomic Health, Inc. (GHDX) to Outperform
-
Lehman Brothers downgrades Genomic Health (GHDX) to Equal-Weight
-
S&P Equity Research Initiates Coverage on Genomic Health (GHDX) with a Hold
-
ThinkEquity Starts Genomic Health (GHDX) at Buy
-
RBC Capital Starts Genomic Health (GHDX) at Sector Perform
-
Cantor Fitzgerald Starts Genomic Health (GHDX) at Buy
-
Piper Jaffray Downgrades GHDX, Sees Regulatory Risk
-
A number of firms start coverage on GHDX
Back to GHDX Stock Lookup
